The center will help Ryvu expand and accelerate its drug research, the company noted. It features 32,300 square feet of laboratory space and will house multiple types of laboratories, including medicinal chemistry, biochemistry, cell and molecular, and analytical chemistry.

The six-floor facility is located in a special economic zone of Krakow, Poland, that provides tax incentives for local companies. It is also near Jagiellonian University and on a street named in honor of the doctor who created the commonly prescribed drug Valium.

Ryvu has obtained occupancy permits and intends to move into the new headquarters at the end of June 2020. However, an official public opening ceremony will not take place until the fall to comply with COVID-19 pandemic regulations.

New COVID-19 R&D initiatives announced
A series of new initiatives aims to simplify scientific literature discovery and acquisition during the COVID-19 crisis, according to Research Solutions....

Universal flu vaccine R&D collaboration established
Clinical-stage biopharmaceutical company TFF Pharmaceuticals has partnered with researchers at the University of Georgia and University of Texas to evaluate...

Funding floodgates open for COVID-19 research
The impacts of the COVID-19 pandemic are being felt around the world. Researchers are working at a record-setting pace to understand the novel coronavirus...